In This Issue
In the Spotlight
Escherichia coli–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer
CXCL13-producing follicular helper CD4+ T cells and IgG specific to Escherichia coli are biomarkers of clinical benefit of neoadjuvant pembrolizumab in patients with muscle-invasive bladder cancer.
A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma
Intratumor myeloid inflammation independently predicts metastatic recurrence after nephrectomy in clear-cell renal cell carcinoma (ccRCC) and can be therapeutically targeted in a novel metastatic ccRCC mouse model.
Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer
Single-cell profiling of pancreatic ductal adenocarcinoma tumor-infiltrating lymphocytes provides a cell-state trajectory and indicates the GZMK+ state as an intermediate between either a GZMB+ cytotoxic state or a CXCL13+ dysfunctional state.
Geospatial Immune Heterogeneity Reflects the Diverse Tumor–Immune Interactions in Intrahepatic Cholangiocarcinoma
Multiregional immunogenomic analyses of intrahepatic cholangiocarcinoma (iCCA) demonstrate the cross-talk between tumor evolution and immune composition, providing novel insight into cancer immunoediting and personalized immunotherapy.
Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer
Chromosomal alteration of BCL-2 leads to poorer outcomes in patients with lymphoma after anti-CD19 CART therapy, but combination of anti-CD19 CART cells overexpressing a BCL-2 mutant with venetoclax leads to synergistic antitumor effects.
Single-cell transcriptomic profiling of the bone marrow of a TET2-induced animal model of clonal hematopoiesis identifies inflammation as a putative driver of leukemic transformation.
The mitochondrial transaminase GOT2 binds directly to fatty acid ligands that regulate the nuclear receptor PPARδ, and this functional interaction critically regulates the immune microenvironment of pancreatic cancer to promote tumor progression.
Loss-of-function alterations in LZTR1, a Cullin-3 RING E3 ubiquitin ligase adapter, and impaired ubiquitin-mediated degradation of RAS proteins via mutations in RIT1 drive clonal hematopoietic transformation.
Schwann cells undergo c-Jun–mediated reprogramming in pancreatic cancer, analogous to their trans-differentiation following trauma, and collectively organize into dynamic tracks that promote cancer cell invasion.
News in Brief
News in Depth
Genome-wide Association Studies